BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 9151959)

  • 21. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells.
    Busso N; Masur SK; Lazega D; Waxman S; Ossowski L
    J Cell Biol; 1994 Jul; 126(1):259-70. PubMed ID: 7517943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.
    Ellis V; Danø K
    Biochem J; 1993 Dec; 296 ( Pt 2)(Pt 2):505-10. PubMed ID: 8257443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
    Høyer-Hansen G; Rønne E; Solberg H; Behrendt N; Ploug M; Lund LR; Ellis V; Danø K
    J Biol Chem; 1992 Sep; 267(25):18224-9. PubMed ID: 1381366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
    Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
    Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
    Kobayashi H; Schmitt M; Goretzki L; Chucholowski N; Calvete J; Kramer M; Günzler WA; Jänicke F; Graeff H
    J Biol Chem; 1991 Mar; 266(8):5147-52. PubMed ID: 1900515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.
    Bonavaud S; Charrière-Bertrand C; Rey C; Leibovitch MP; Pedersen N; Frisdal E; Planus E; Blasi F; Gherardi R; Barlovatz-Meimon G
    J Cell Sci; 1997 May; 110 ( Pt 9)():1083-9. PubMed ID: 9175704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
    Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
    Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
    List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
    Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
    Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
    EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells.
    Mustjoki S; Tapiovaara H; Sirén V; Vaheri A
    Leukemia; 1998 Feb; 12(2):164-74. PubMed ID: 9519778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells.
    Tang H; Kerins DM; Hao Q; Inagami T; Vaughan DE
    J Biol Chem; 1998 Jul; 273(29):18268-72. PubMed ID: 9660790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
    Friess H; Duarte R; Kleeff J; Fukuda A; Tang WH; Graber H; Schilling M; Zimmermann A; Korc M; Büchler MW
    Surgery; 1998 Jul; 124(1):79-86. PubMed ID: 9663255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM; Strickland S
    J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcellular distribution of urokinase and urokinase receptor in human neutrophils determined by immunoelectron microscopy.
    Pedersen TL; Plesner T; Horn T; Høyer-Hansen G; Sørensen S; Hansen NE
    Ultrastruct Pathol; 2000; 24(3):175-82. PubMed ID: 10914429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M
    Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
    Reinartz J; Link J; Todd RF; Kramer MD
    Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
    Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
    Baker MS; Liang XM; Doe WF
    Biochim Biophys Acta; 1992 Sep; 1117(2):143-52. PubMed ID: 1381963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
    Mizukami IF; Todd RF
    J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.